Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 500 shares of the stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $34.98, for a total transaction of $17,490.00. Following the completion of the transaction, the insider directly owned 286,016 shares of the company's stock, valued at approximately $10,004,839.68. The trade was a 0.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Krishnaswamy Yeleswaram also recently made the following trade(s):
- On Tuesday, April 14th, Krishnaswamy Yeleswaram sold 10,200 shares of Rapport Therapeutics stock. The shares were sold at an average price of $35.08, for a total transaction of $357,816.00.
- On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.97, for a total transaction of $320,500.05.
- On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.90, for a total transaction of $12,564.00.
Rapport Therapeutics Price Performance
Shares of NASDAQ:RAPP opened at $36.15 on Wednesday. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -12.64 and a beta of 1.09. The firm has a 50 day simple moving average of $29.59 and a 200 day simple moving average of $28.36. Rapport Therapeutics, Inc. has a one year low of $7.73 and a one year high of $42.27.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.07). As a group, analysts expect that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.
Hedge Funds Weigh In On Rapport Therapeutics
Several large investors have recently modified their holdings of the business. Meeder Asset Management Inc. bought a new position in Rapport Therapeutics during the fourth quarter worth $37,000. Russell Investments Group Ltd. bought a new position in Rapport Therapeutics during the third quarter worth $43,000. Strs Ohio raised its stake in Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company's stock worth $62,000 after buying an additional 400 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Rapport Therapeutics by 64.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock worth $70,000 after buying an additional 905 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Rapport Therapeutics during the third quarter worth $143,000.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the stock. TD Cowen reaffirmed a "buy" rating on shares of Rapport Therapeutics in a research note on Monday, March 9th. BTIG Research raised their price target on shares of Rapport Therapeutics to $47.00 and gave the company a "buy" rating in a research note on Monday, March 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Thursday, January 22nd. Citigroup reaffirmed a "market outperform" rating on shares of Rapport Therapeutics in a research note on Tuesday, March 10th. Finally, Wall Street Zen downgraded shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $53.83.
Check Out Our Latest Analysis on RAPP
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
